Entre sel et gènes ou pharmacogénomique des antihypertenseurs
|Published in||Revue médicale suisse. 2006, vol. 2, no. 61, p. 986-991|
|Abstract||Pharmacogenomics studies the links between polymorphisms (genetic variants) and the variability of the response to some treatments in a given individual. Pharmacogenomics thus allows to explore polymorphisms that could potentially explain heterogeneous efficacy of diuretics, ACE inhibitors or angiotensin receptor blockers, beta-blockers and calcium channel blockers among populations of varied ethnical origin. There have been many studies on the relation between the efficacy of these treatments and the specific polymorphisms involved in the regulation of blood pressure. So far, no unique mutation is by itself predictive of the therapeutic response to these drugs; more elaborated polygenetic models are required so that pharmacogenomics can one day offer an individualized prescription for a complicated disease such as high blood pressure.|
|Keywords||Antihypertensive Agents/pharmacology/therapeutic use — Blood Pressure/drug effects — Genomics — Humans — Hypertension/drug therapy/genetics/metabolism — Polymorphism, Genetic — Sodium/metabolism|
This document has no fulltext available yet, but you can contact its author by using the form below.
|Research group||Groupe Desmeules Jules (pharmacologie/toxicologie) (567)|
|ERNANDEZ, Thomas et al. Entre sel et gènes ou pharmacogénomique des antihypertenseurs. In: Revue médicale suisse, 2006, vol. 2, n° 61, p. 986-991. https://archive-ouverte.unige.ch/unige:90095|